Wysocki NA, et al. - Given that the safety of leaving tPA (tissue-type plasminogen activator)-treated patients at a presenting (spoke) hospital (drip-and-stay) or transferring patients to a central treating (hub) hospital (drip-and-ship) is not known, researchers compared outcomes between drip-and-ship and drip-and-stay patients treated with tPA via telemedicine in this retrospective study. Between September 2015 and December 2016, patients treated with tPA at 17 spoke hospitals were retrospectively identified. Outcomes did not differ between drip-and-ship and drip-and-stay patients treated in the network, although the study might be strong enough to measure small differences.